Quest Diagnostics (DGX) Could Be 3% Undervalued After Raised 2026 Guidance
Quest Diagnostics (DGX) raised its full year 2026 revenue and earnings guidance after its second quarter results and ongoing share repurchases, giving investors fresh information on business momentum and projected profitability.
See our latest analysis for Quest Diagnostics.
Quest Diagnostics' recent earnings beat, higher 2026 guidance and continued buybacks have coincided with a 33.4% year to date share price return and a 40.55% 1 year total shareholder return, which suggests momentum has been building rather than fading.
If this kind of sustained momentum has your attention, it can be useful to see what else is working in related areas of healthcare, including companies using AI in diagnostics and treatment planning via the 41 healthcare AI stocks.
For Quest Diagnostics, this sharp rerating can look like a simple mood shift in the market or a clearer reflection of improved earnings power and guidance. Which of those views makes more sense once you look at valuation next?
Most Popular Narrative: 3.1% Undervalued
Quest Diagnostics is trading at $231.84 against a widely followed fair value estimate of $239.38, which points to a small valuation gap that hinges on a detailed growth and margin story.
Ongoing growth in advanced and preventive testing including cardiometabolic, autoimmune, brain health, oncology, and women's/reproductive diagnostics as well as robust demand from functional medicine and wellness-focused consumers, are driving higher test volumes and increasing test-per-requisition, which supports both revenue growth and margin expansion.
Curious what kind of revenue build, margin lift and valuation multiple are baked into that narrative for Quest Diagnostics. The core assumptions are tighter than you might think. The projections rely on specific growth rates, profitability targets and a defined discount rate that need to line up cleanly to reach that fair value.
Result: Fair Value of $239.38 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points for Quest Diagnostics, including potential reimbursement cuts and higher wage and automation costs that could squeeze the margin story that investors are watching.
Find out about the key risks to this Quest Diagnostics narrative.
Next Steps
With both risks and rewards in play around Quest Diagnostics, it makes sense to review the full picture now and decide where you stand. To see how those trade offs stack up in one place, take a closer look at the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Quest Diagnostics?
If Quest Diagnostics has sharpened your focus, now is a good moment to broaden your watchlist with other focused ideas sourced from Simply Wall Street screeners.
- Target smoother portfolio swings by reviewing companies highlighted in the 84 resilient stocks with low risk scores and see which stocks line up with your risk comfort.
- Hunt for strong businesses at appealing prices using the 51 high quality undervalued stocks and compare how their potential stacks up against Quest Diagnostics.
- Strengthen your income stream by checking out the 8 dividend fortresses and see which higher yielding stocks might deserve a closer look.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com